Abstract

RNA interference represents a potent intervention for cancer treatment but requires a robust delivery agent for transporting gene-modulating molecules, such as small interfering RNAs (siRNAs). Although numerous molecular approaches for siRNA delivery are adequate in vitro, delivery to therapeutic targets in vivo is limited by payload integrity, cell targeting, efficient cell uptake, and membrane penetration. We constructed nonviral biomaterials to transport small nucleic acids to cell targets, including tumor cells, on the basis of the self-assembling and cell-penetrating activities of the adenovirus capsid penton base. Our recombinant penton base chimera contains polypeptide domains designed for noncovalent assembly with anionic molecules and tumor homing. Here, structural modeling, molecular dynamics simulations, and functional assays suggest that it forms pentameric units resembling viral capsomeres that assemble into larger capsid-like structures when combined with siRNA cargo. Pentamerization forms a barrel lined with charged residues mediating pH-responsive dissociation and exposing masked domains, providing insight on the endosomolytic mechanism. The therapeutic impact was examined on tumors expressing high levels of HER3/ErbB3 that are resistant to clinical inhibitors. Our findings suggest that our construct may utilize ligand mimicry to avoid host attack and target the siRNA to HER3+ tumors by forming multivalent capsid-like structures.

Highlights

  • HER3/ErbB3 promotes the growth of an expanding range of tumor types [1,2,3,4,5,6,7,8,9,10,11,12,13]

  • The results presented here show that HPK is a HER3targeted biocarrier for systemic homing of RNA interference (RNAi) to HER3-expressing tumors––including triple-negative breast tumors––in vivo

  • The combination of molecular dynamics (MD) simulations and functional assays revealed that HPK forms endosomolytic capsomeres that assemble with small interfering RNAs (siRNAs) into serum-stable nucleocapsids whose ligand multivalencies hinder immune recognition while facilitating robust receptor interaction and cell uptake

Read more

Summary

Introduction

HER3/ErbB3 promotes the growth of an expanding range of tumor types [1,2,3,4,5,6,7,8,9,10,11,12,13]. There is growing interest for the targeting of HER3 in the clinic It contains an inactive kinase domain, making it an impractical target for signal inhibition [19,20], the increased density of HER3 on the surfaces of resistant tumor cells provides a useful biomarker for active targeting of those cells and a potentially valuable portal for the accumulation of ErbB-directed therapeutic-loaded nanocarriers. We have shown that our HER3-homing protein construct, HPK, mediates the targeted delivery of chemotherapeutic compounds to trastuzumab (Herceptin)-resistant breast tumors, which display high cell surface densities of HER3 [21]. As these tumors can resist conventional tumoricidal drugs, the targeted delivery of alternative cargo––such as small interfering RNA (siRNA)––may provide useful therapeutic options. The delivery of siRNA via HER3-mediated targeting has not yet been reported, likely because HER3 is a recently emerging tumor target and corresponding ligands are not widely available or widely explored for directing therapeutic carriers

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.